N,N-二甲基-3-吗啉甲胺 | 128454-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: N,N-二甲基-3-吗啉甲胺
• 英文名称: dimethyl(morpholin-3-ylmethyl)amine
• 英文别名: N,N-Dimethyl-1-(morpholin-3-yl)methanamine；N,N-dimethyl-1-morpholin-3-ylmethanamine
• CAS: 128454-20-6
• 化学式: C₇H₁₆N₂O
• 分子量: 144.217
• InChiKey: BJCCGQRWHQSBLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  198.8±15.0 °C(Predicted)
• 密度：
  0.931±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-二甲基-3-吗啉甲胺 、 5chloro-3-oxoindan-1-carbonyl chloride 以 三乙胺 为溶剂， 以to afford 1.03 g of the title compound, melting at 230°-240° C.的产率得到4-(5-Chloro-3-oxoindan-1-carbonyl)-3-(dimethylaminomethyl)morpholine hydrochloride
  参考文献：
  名称：

  Analgesic thiomorpholins their preparation, and pharmaceutical

  摘要：

  镇痛化合物的一般式（I）为：##STR1## 其中，R.sup.1和R.sup.2分别代表氢或C.sub.1-C.sub.6烷基，或者R.sup.1和R.sup.2与它们所附着的氮原子一起形成杂环；E代表亚甲基，硫，氧或亚氨基团，可选地被C.sub.1-C.sub.6烷基或芳基烷基取代；环A是芳基或杂芳基环，可选地被取代；R.sup.3是氢或C.sub.1-C.sub.6烷基，R.sup.4是氢或R.sup.3和R.sup.4一起代表公式（IV）的一个基团：--(CR.sup.aR.sup.a).sub.m--C(.dbd.Y)--（IV）（其中R.sup.a和R.sup.a是C.sub.1-C.sub.6烷基或氢，最多3个烷基基团，m为1、2或3，Y为两个氢或氧）；但是当E代表亚甲基时，R.sup.3是C.sub.1-C.sub.6烷基或R.sup.3和R.sup.4一起代表公式（IV）的一个基团。

  公开号：

  US05021413A1

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• [EN] DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDROPYRIMIDOPIRYMIDINE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010067888A1

  公开（公告）日：2010-06-17

  The invention relates to compounds represented by the general formula (I) and the like. In the formula, Ar1 denotes an aryl or heteroaryl group which may have a substituent; R1 denotes a hydrogen atom, or denotes a C1-C6 alkyl, aryl, aralkyl or heteroaryl group which may have a substituent; R2 denotes an aralkyl group or a group represented by the formula (a); and R3 denotes a hydrogen atom or a C1-C6 alkyl group. The compounds of the invention have an excellent Weel kinase inhibitory effect, and therefore are useful in the field of medicine, especially in the field of treatment of various cancers.

  本发明涉及由一般式(I)等表示的化合物。在该式中，Ar1表示可能具有取代基的芳基或杂环芳基；R1表示氢原子，或表示可能具有取代基的C1-C6烷基，芳基，芳基烷基或杂环芳基；R2表示芳基烷基或由式(a)表示的基团；R3表示氢原子或C1-C6烷基。本发明的化合物具有优异的Weel激酶抑制作用，因此在医学领域，特别是在各种癌症治疗领域中非常有用。
• [EN] DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE<br/>[FR] DÉRIVÉ DE DIHYDROPYRIMIDOPYRIMIDINE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010067886A1

  公开（公告）日：2010-06-17

  The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar1 is an optionally substituted aryl or heteroaryl group; R1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy.

  本发明涉及一种通式（I）的化合物，其中Ar1是一个可选取代的芳基或杂环芳基基团；R1是氢原子，可选取代的C1-C6烷基基团，或可选取代的芳基、芳基烷基或杂环芳基基团；R2是可选取代的芳基、芳基烷基或杂环芳基基团；R3是氢原子或C1-C6烷基基团。本发明的化合物具有出色的Wee1激酶抑制作用，因此在医学领域特别是各种癌症治疗方面非常有用。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。
• Process for preparing analgesic compounds
  申请人：Sankyo Company, Limited

  公开号：US05656758A1

  公开（公告）日：1997-08-12

  A process for preparing a compound of the formula (I): ##STR1## in which, R.sup.1 and R.sup.2 each represents hydrogen or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a heterocycle; E represents methylene, sulfur, oxygen or imino group optionally substituted with C.sub.1 -C.sub.6 alkyl or aralkyl; ring A is aryl or heteroaryl ring, optionally substituted; R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl and R.sup.4 is hydrogen or R.sup.3 and R.sup.4 together represent a group of formula (IV): --(CR.sup.a R.sup.a).sub.m --C(.dbd.Y)-- (IV) (wherein R.sup.a and R.sup.a is C.sub.1 -C.sub.6 alkyl or hydrogen, up to a maximum of 3 alkyl groups, m is 1, 2, or 3, and Y is two hydrogens or oxygen); provided that when E represents a methylene group, then R.sup.3 is a C.sub.1 -C.sub.6 alkyl group or R.sup.3 and R.sup.4 together represent a group of the formula (IV), which comprises reacting an acid of the formula ##STR2## with an amine of the formula ##STR3##

  一种制备化合物(I)的方法：其中，R.sup.1和R.sup.2分别表示氢或C.sub.1-C.sub.6烷基，或者R.sup.1和R.sup.2与它们所连接的氮原子形成杂环；E表示亚甲基、硫、氧或亚胺基，可选地被C.sub.1-C.sub.6烷基或芳基烷基取代；环A是芳基或杂芳基环，可选地被取代；R.sup.3是氢或C.sub.1-C.sub.6烷基，R.sup.4是氢或R.sup.3和R.sup.4共同表示式(IV)的一个组，其中，--(CR.sup.aR.sup.a).sub.m--C(.dbd.Y)--(IV)（其中，R.sup.a和R.sup.a是C.sub.1-C.sub.6烷基或氢，最多3个烷基基团，m为1、2或3，Y为两个氢或氧）；但当E表示亚甲基时，R.sup.3是C.sub.1-C.sub.6烷基或R.sup.3和R.sup.4共同表示式(IV)的一个组。该方法包括将式为##STR2##的酸与式为##STR3##的胺反应。